First patient dosed in Deciphera’s Phase III INTREPID study
The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance